{"schema_version":"secwatch.filing_event.v1","accession":"0001739614-24-000031","form_type":"8-K","ticker":null,"cik":"0001739614","company_name":"Inhibrx, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.837372+00:00","generated_at":"2026-06-02T06:33:16.978833+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Inhibrx reports Q1 results; Sanofi merger with $30/shr cash, CVR, and spin-off set for May 30","bullets":["Sanofi to acquire INBRX-101 assets; shareholders receive $30/shr cash + $5 CVR + 1/4 share of New Inhibrx.","Merger closing and spin-off expected May 30; special meeting May 24; when-issued trading of New Inhibrx (INXB) starts May 16.","Q1 net loss $78.7M ($1.44/shr) vs $48.9M ($1.12/shr) YoY; R&D expense up 71% to $63.9M.","Cash $252.5M at Mar 31, down from $277.9M at Dec 31; $38.7M in stock option proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001739614-24-000031","json":"https://secwatch.observer/filing/0001739614-24-000031.json","markdown":"https://secwatch.observer/filing/0001739614-24-000031.md","text":"https://secwatch.observer/filing/0001739614-24-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739614/000173961424000031/0001739614-24-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739614/000173961424000031/inhibrx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:33:16.978833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eff33d3d0f3170e0495c69564ceb1e50cbbe7ee9","claim":"Inhibrx, Inc. reported the first quarter of 2024 results: net income $78.7 million, EPS $1.44 per share.","evidence_excerpt":"Net loss was $78.7 million during the first quarter of 2024, or $1.44 per share, compared to $48.9 million during the first quarter of 2023, or $1.12 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739614/000173961424000031/0001739614-24-000031-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Net income","value":"$78.7 million"},{"label":"EPS","value":"$1.44 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}